Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group announced that its HER2 bispecific antibody Anbenitamab (KN026), co-developed with Jiangsu Alphamab Oncology and combined with its in-house albumin-bound docetaxel (HB1801), met the primary endpoint of total pathological complete response in a Phase III neoadjuvant trial for early or locally advanced HER2-positive breast cancer. The regimen showed a statistically and clinically significant improvement in complete response versus current standard therapy, reinforcing CSPC’s positioning in oncology biologics and nanomedicine, and adding clinical momentum to Anbenitamab’s expanding development program in breast and gastric cancers.
The Neo-Healer (KN026–004) study enrolled about 520 patients in China to compare KN026 plus HB1801-based regimens with trastuzumab, pertuzumab and docetaxel-based neoadjuvant therapy, with detailed data to be presented at an upcoming international conference. Anbenitamab already has an accepted filing in China for HER2-positive advanced gastric cancer and holds U.S. Orphan Drug and Chinese Breakthrough Therapy designations, while HB1801 leverages CSPC’s nanomedicine platform to offer a solvent-free docetaxel option that aims to improve safety, dosing flexibility and patient convenience across solid tumor indications.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on innovative therapies and advanced drug-delivery technologies. Through subsidiaries such as Shanghai JMT-BIO Technology, it develops biologics like HER2-targeted antibodies and nanomedicine-based formulations, targeting major oncology indications in the Chinese Mainland market.
Average Trading Volume: 113,202,693
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$106.9B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.